X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
chemotherapy (3) 3
disease-free survival (3) 3
hematology, oncology and palliative medicine (3) 3
humans (3) 3
index medicus (3) 3
oncology (3) 3
adult (2) 2
aged (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
breast cancer (2) 2
breast neoplasms - drug therapy (2) 2
breast neoplasms - pathology (2) 2
cancer (2) 2
care and treatment (2) 2
female (2) 2
middle aged (2) 2
neoplasm staging (2) 2
therapy (2) 2
trastuzumab (2) 2
adenocarcinoma - chemistry (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - pathology (1) 1
administration, oral (1) 1
aged, 80 and over (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, monoclonal, humanized - pharmacokinetics (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
biomarkers, tumor - genetics (1) 1
brain metastases (1) 1
breast neoplasms - chemistry (1) 1
breast neoplasms - genetics (1) 1
breast neoplasms - mortality (1) 1
cancer therapies (1) 1
carcinoma (1) 1
central nervous system neoplasms - chemically induced (1) 1
central nervous system neoplasms - secondary (1) 1
chemotherapy, adjuvant - adverse effects (1) 1
clinical trials as topic (1) 1
comparative analysis (1) 1
cyclophosphamide - administration & dosage (1) 1
disease progression (1) 1
diseases (1) 1
dna mutational analysis (1) 1
doxorubicin - administration & dosage (1) 1
drug administration schedule (1) 1
epirubicin (1) 1
epirubicin - administration & dosage (1) 1
eq-5d (1) 1
european-organization (1) 1
fluorouracil - administration & dosage (1) 1
gene mutations (1) 1
genetic predisposition to disease (1) 1
hospitals (1) 1
imidazoles - administration & dosage (1) 1
imidazoles - adverse effects (1) 1
imidazoles - therapeutic use (1) 1
indoles - administration & dosage (1) 1
indoles - adverse effects (1) 1
indoles - therapeutic use (1) 1
infusions, intravenous (1) 1
infusions, subcutaneous (1) 1
intention to treat analysis (1) 1
map kinase kinase kinases - antagonists & inhibitors (1) 1
map kinase kinase kinases - metabolism (1) 1
medical colleges (1) 1
melanoma (1) 1
melanoma - drug therapy (1) 1
melanoma - genetics (1) 1
melanoma - mortality (1) 1
melanoma - secondary (1) 1
metastasis (1) 1
mutation (1) 1
neoadjuvant therapy - methods (1) 1
neoplasm grading (1) 1
nervous-system metastases (1) 1
oncology, experimental (1) 1
oximes - administration & dosage (1) 1
oximes - adverse effects (1) 1
oximes - therapeutic use (1) 1
paclitaxel (1) 1
phenotype (1) 1
population (1) 1
product development (1) 1
prospective studies (1) 1
protein kinase inhibitors - administration & dosage (1) 1
protein kinase inhibitors - adverse effects (1) 1
protein kinase inhibitors - therapeutic use (1) 1
proto-oncogene proteins b-raf - antagonists & inhibitors (1) 1
proto-oncogene proteins b-raf - genetics (1) 1
pyridones - administration & dosage (1) 1
pyridones - adverse effects (1) 1
pyridones - therapeutic use (1) 1
pyrimidinones - administration & dosage (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 3, pp. 244 - 248
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 9, pp. 869 - 878
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.